Clinical trial
Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular…
NCT00078221 · OccuLogix, Industry · Unknown status
Key facts
| NCT number | NCT00078221 |
|---|---|
| Title | Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD) |
| Lead sponsor | OccuLogix, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Device |
| Interventions | Rheopheresis blood filtration |
| Enrollment | 180 |
| Start date | Aug 1, 1999 |
| Completion | Dec 1, 2005 |
| First posted | Mar 1, 2004 |
| Last update posted | May 9, 2008 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: